Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevudine Extension Study in Chronic Hepatitis B
NCT00362505Phase 3Terminated
- Sponsor
- Bukwang Pharmaceutical
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of clevudine in Chronic Hepatitis B (CHB), sponsored by Bukwang Pharmaceutical. Primary endpoints: Change from baseline in HBV DNA, Clinically measured adverse events and 3 more. Started Jun 2004; status: terminated.
02
Drugs
clevudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00362505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362505.